Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.

Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T.

Cancer. 2019 Nov 26. doi: 10.1002/cncr.32503. [Epub ahead of print]

PMID:
31769875
2.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Huber RM, Hansen KH, Paz-Ares Rodríguez L, West HL, Reckamp KL, Leighl NB, Tiseo M, Smit EF, Kim DW, Gettinger SN, Hochmair MJ, Kim SW, Langer CJ, Ahn MJ, Kim ES, Kerstein D, Groen HJM, Camidge DR.

J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645-7. doi: 10.1016/j.jtho.2019.11.004. [Epub ahead of print]

3.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Chan Ahn Y, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F.

J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640-8. doi: 10.1016/j.jtho.2019.10.022. [Epub ahead of print] Review.

PMID:
31733357
4.

Pipetting-based immunoassay for point-of-care testing: Application for detection of the influenza A virus.

Noh JY, Yoon SW, Kim Y, Lo TV, Ahn MJ, Jung MC, Le TB, Na W, Song D, Le VP, Haam S, Jeong DG, Kim HK.

Sci Rep. 2019 Nov 13;9(1):16661. doi: 10.1038/s41598-019-53083-8.

5.

Transgenic sweetpotato plants overexpressing tocopherol cyclase display enhanced α-tocopherol content and abiotic stress tolerance.

Kim SE, Lee CJ, Ji CY, Kim HS, Park SU, Lim YH, Park WS, Ahn MJ, Bian X, Xie Y, Guo X, Kwak SS.

Plant Physiol Biochem. 2019 Nov;144:436-444. doi: 10.1016/j.plaphy.2019.09.046. Epub 2019 Sep 30.

PMID:
31639559
6.

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

Ahn MJ, Han JY, Lee KH, Kim SW, Kim DW, Lee YG, Cho EK, Kim JH, Lee GW, Lee JS, Min YJ, Kim JS, Lee SS, Kim HR, Hong MH, Ahn JS, Sun JM, Kim HT, Lee DH, Kim S, Cho BC.

Lancet Oncol. 2019 Oct 3. pii: S1470-2045(19)30504-2. doi: 10.1016/S1470-2045(19)30504-2. [Epub ahead of print]

PMID:
31587882
7.

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.

Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Kodani M, Kitagawa Y.

Lancet Oncol. 2019 Nov;20(11):1506-1517. doi: 10.1016/S1470-2045(19)30626-6. Epub 2019 Sep 30. Erratum in: Lancet Oncol. 2019 Nov;20(11):e613.

PMID:
31582355
8.

Particulate matter-induced senescence of skin keratinocytes involves oxidative stress-dependent epigenetic modifications.

Ryu YS, Kang KA, Piao MJ, Ahn MJ, Yi JM, Bossis G, Hyun YM, Park CO, Hyun JW.

Exp Mol Med. 2019 Sep 24;51(9):108. doi: 10.1038/s12276-019-0305-4.

9.
10.

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.

Jung H, Kim HS, Kim JY, Sun JM, Ahn JS, Ahn MJ, Park K, Esteller M, Lee SH, Choi JK.

Nat Commun. 2019 Sep 19;10(1):4278. doi: 10.1038/s41467-019-12159-9.

11.

Particulate Matter 2.5 Mediates Cutaneous Cellular Injury by Inducing Mitochondria-Associated Endoplasmic Reticulum Stress: Protective Effects of Ginsenoside Rb1.

Piao MJ, Kang KA, Zhen AX, Fernando PDSM, Ahn MJ, Koh YS, Kang HK, Yi JM, Choi YH, Hyun JW.

Antioxidants (Basel). 2019 Sep 9;8(9). pii: E383. doi: 10.3390/antiox8090383.

12.

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial.

Guo Y, Ahn MJ, Chan A, Wang CH, Kang JH, Kim SB, Bello M, Arora RS, Zhang Q, He X, Li P, Dechaphunkul A, Kumar V, Kamble K, Li W, Kandil A, Cohen EEW, Geng Y, Zografos E, Tang PZ.

Ann Oncol. 2019 Sep 10. pii: mdz388. doi: 10.1093/annonc/mdz388. [Epub ahead of print]

PMID:
31501887
13.

Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing.

Kim HS, Cha H, Kim J, Park WY, Choi YL, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.

Eur J Cancer. 2019 Oct;120:65-74. doi: 10.1016/j.ejca.2019.08.001. Epub 2019 Sep 4.

PMID:
31493723
14.

Predictive and Prognostic Value of 18F-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer.

Moon SH, Sun JM, Ahn JS, Park K, Kim BT, Lee KH, Ahn MJ, Choi JY.

Sci Rep. 2019 Aug 21;9(1):12215. doi: 10.1038/s41598-019-48674-4.

15.

Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study.

Bang OY, Chung JW, Cho YH, Oh MJ, Seo WK, Kim GM, Ahn MJ.

Stroke. 2019 Oct;50(10):2944-2947. doi: 10.1161/STROKEAHA.119.026373. Epub 2019 Aug 9.

PMID:
31394991
16.

Eckol Inhibits Particulate Matter 2.5-Induced Skin Keratinocyte Damage via MAPK Signaling Pathway.

Zhen AX, Hyun YJ, Piao MJ, Fernando PDSM, Kang KA, Ahn MJ, Yi JM, Kang HK, Koh YS, Lee NH, Hyun JW.

Mar Drugs. 2019 Jul 27;17(8). pii: E444. doi: 10.3390/md17080444.

17.

Chemical constituents of the root bark of Ulmus davidiana var. japonica and their potential biological activities.

So HM, Yu JS, Khan Z, Subedi L, Ko YJ, Lee IK, Park WS, Chung SJ, Ahn MJ, Kim SY, Kim KH.

Bioorg Chem. 2019 Oct;91:103145. doi: 10.1016/j.bioorg.2019.103145. Epub 2019 Jul 25.

PMID:
31357073
18.

A single amino acid change at position 96 (Arg to His) of the sweetpotato Orange protein leads to carotenoid overaccumulation.

Kim SE, Kim HS, Wang Z, Ke Q, Lee CJ, Park SU, Lim YH, Park WS, Ahn MJ, Kwak SS.

Plant Cell Rep. 2019 Nov;38(11):1393-1402. doi: 10.1007/s00299-019-02448-4. Epub 2019 Jul 25.

PMID:
31346717
19.

Osimertinib in Patients with T790M Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies.

Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS.

Cancer Res Treat. 2019 Jul 23. doi: 10.4143/crt.2019.200. [Epub ahead of print]

20.

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.

Lee K, Jung HA, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Cancer Res Treat. 2019 Jul 26. doi: 10.4143/crt.2019.186. [Epub ahead of print]

21.

Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.

Park S, Shim JH, Lee B, Cho I, Park WY, Kim Y, Lee SH, Choi Y, Han J, Ahn JS, Ahn MJ, Park K, Sun JM.

Lung Cancer. 2019 Aug;134:7-15. doi: 10.1016/j.lungcan.2019.05.024. Epub 2019 May 24.

PMID:
31319998
22.

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabrò L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Oct;14(10):1794-1806. doi: 10.1016/j.jtho.2019.06.010. Epub 2019 Jun 20.

23.

Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer.

Bak SH, Park H, Sohn I, Lee SH, Ahn MJ, Lee HY.

Sci Rep. 2019 Jun 19;9(1):8730. doi: 10.1038/s41598-019-45117-y.

24.

Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.

Kim Y, Kim CH, Lee HY, Lee SH, Kim HS, Lee S, Cha H, Hong S, Kim K, Seo SW, Sun JM, Ahn MJ, Ahn JS, Park K.

J Thorac Oncol. 2019 Sep;14(9):1608-1618. doi: 10.1016/j.jtho.2019.05.033. Epub 2019 Jun 11. Erratum in: J Thorac Oncol. 2019 Nov;14(11):2023.

PMID:
31195179
25.

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Felip E, Goldman JW, Scalzo C, Jensen E, Kush DA, Hui R.

J Clin Oncol. 2019 Oct 1;37(28):2518-2527. doi: 10.1200/JCO.19.00934. Epub 2019 Jun 2.

26.

Gut microbiome differences between wild and captive black rhinoceros - implications for rhino health.

Gibson KM, Nguyen BN, Neumann LM, Miller M, Buss P, Daniels S, Ahn MJ, Crandall KA, Pukazhenthi B.

Sci Rep. 2019 May 28;9(1):7570. doi: 10.1038/s41598-019-43875-3.

27.

DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC.

Park S, Lee H, Lee B, Lee SH, Sun JM, Park WY, Ahn JS, Ahn MJ, Park K.

J Thorac Oncol. 2019 Sep;14(9):1640-1650. doi: 10.1016/j.jtho.2019.05.014. Epub 2019 May 22.

PMID:
31125737
28.

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.

Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.

Invest New Drugs. 2019 May 24. doi: 10.1007/s10637-019-00795-3. [Epub ahead of print]

PMID:
31124056
29.

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.

Park S, Joung JG, Min YW, Nam JY, Ryu D, Oh D, Park WY, Lee SH, Choi Y, Ahn JS, Ahn MJ, Park K, Sun JM.

J Immunother Cancer. 2019 May 16;7(1):128. doi: 10.1186/s40425-019-0609-x.

30.

Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.

Park E, Choi YL, Ahn MJ, Han J.

Pathol Res Pract. 2019 Jul;215(7):152441. doi: 10.1016/j.prp.2019.152441. Epub 2019 May 6.

PMID:
31085007
31.

A new anti-Helicobacter pylori juglone from Reynoutria japonica.

Khalil AAK, Park WS, Lee J, Kim HJ, Akter KM, Goo YM, Bae JY, Chun MS, Kim JH, Ahn MJ.

Arch Pharm Res. 2019 Jun;42(6):505-511. doi: 10.1007/s12272-019-01160-x. Epub 2019 May 9.

PMID:
31073878
32.

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?

Ahn MJ.

J Thorac Oncol. 2019 May;14(5):766-767. doi: 10.1016/j.jtho.2019.03.005. No abstract available.

PMID:
31027741
33.

Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

Remon J, Ahn MJ, Girard N, Johnson M, Kim DW, Lopes G, Pillai RN, Solomon B, Villacampa G, Zhou Q.

J Thorac Oncol. 2019 Jul;14(7):1134-1155. doi: 10.1016/j.jtho.2019.03.022. Epub 2019 Apr 16. Review.

PMID:
31002952
34.

Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells.

Kang KA, Piao MJ, Hyun YJ, Zhen AX, Cho SJ, Ahn MJ, Yi JM, Hyun JW.

Exp Mol Med. 2019 Apr 15;51(4):40. doi: 10.1038/s12276-019-0238-y.

35.

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.

Cho WK, Oh D, Kim HK, Ahn YC, Noh JM, Shim YM, Zo JI, Choi YS, Sun JM, Lee SH, Ahn MJ, Park K, Nam H.

Radiother Oncol. 2019 Apr;133:87-92. doi: 10.1016/j.radonc.2019.01.005. Epub 2019 Jan 21.

PMID:
30935586
36.

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.

Cho JH, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Sun JM.

J Cancer Res Clin Oncol. 2019 May;145(5):1341-1349. doi: 10.1007/s00432-019-02889-0. Epub 2019 Mar 21.

PMID:
30900155
37.

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

Lee K, Kim Y, Jung HA, Lee SH, Ahn JS, Ahn MJ, Park K, Choi YL, Sun JM.

Lung Cancer. 2019 Apr;130:87-92. doi: 10.1016/j.lungcan.2019.01.012. Epub 2019 Jan 28.

PMID:
30885357
38.

Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study.

Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB.

Lancet Respir Med. 2019 Apr;7(4):347-357. doi: 10.1016/S2213-2600(18)30500-9. Epub 2019 Mar 12.

PMID:
30876831
39.

Down-regulation of lycopene ε-cyclase expression in transgenic sweetpotato plants increases the carotenoid content and tolerance to abiotic stress.

Ke Q, Kang L, Kim HS, Xie T, Liu C, Ji CY, Kim SH, Park WS, Ahn MJ, Wang S, Li H, Deng X, Kwak SS.

Plant Sci. 2019 Apr;281:52-60. doi: 10.1016/j.plantsci.2019.01.002. Epub 2019 Jan 10.

PMID:
30824061
40.

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.

Shin SH, Park HY, Im Y, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee HY, Lee SH.

Int J Cancer. 2019 Nov 1;145(9):2433-2439. doi: 10.1002/ijc.32235. Epub 2019 Mar 25.

PMID:
30807641
41.

Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.

Yang B, Lee H, Um SW, Kim K, Zo JI, Shim YM, Jung Kwon O, Lee KS, Ahn MJ, Kim H.

Lung Cancer. 2019 Mar;129:28-34. doi: 10.1016/j.lungcan.2018.12.027. Epub 2018 Dec 28.

PMID:
30797488
42.

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors.

Jung KH, LoRusso P, Burris H, Gordon M, Bang YJ, Hellmann MD, Cervantes A, de Olza MO, Marabelle A, Hodi FS, Ahn MJ, Emens LA, Barlesi F, Hamid O, Calvo E, McDermott D, Soliman H, Rhee I, Lin R, Pourmohamad T, Suchomel J, Tsuhako A, Morrissey K, Mahrus S, Morley R, Pirzkall A, Davis SL.

Clin Cancer Res. 2019 Jun 1;25(11):3220-3228. doi: 10.1158/1078-0432.CCR-18-2740. Epub 2019 Feb 15.

PMID:
30770348
43.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Berry S, Giraldo N, Nguyen P, Green B, Xu H, Ogurtsova A, Soni A, Succaria F, Wang D, Roberts C, Stein J, Engle E, Pardoll D, Anders R, Cottrell T, Taube JM, Tran B, Voskoboynik M, Kuo J, Bang YL, Chung HC, Ahn MJ, Kim SW, Perera A, Freeman D, Achour I, Faggioni R, Xiao F, Ferte C, Lemech C, Meric-Bernstam F, Werner T, Hodi S, Messersmith W, Lewis N, Talluto C, Dostalek M, Tao A, McWhirter S, Trujillo D, Luke J, Xu C, BoMarelli, Qi J, Qin G, Yu H, Jenkins M, Lo KM, Halle JP, Lan Y, Taylor M, Vogelzang N, Cohn A, Stepan D, Shumaker R, Dutcus C, Guo M, Schmidt E, Rasco D, Brose M, Vogelzang N, Di Simone C, Jain S, Richards D, Encarnacion C, Rasco D, Shumaker R, Dutcus C, Stepan D, Guo M, Schmidt E, Taylor M, Vogelzang N, Encarnacion C, Cohn A, Di Simone C, Rasco D, Richards D, Taylor M, Dutcus C, Stepan D, Shumaker R, Guo M, Schmidt E, Mier J, An J, Yang YY, Lee WH, Yang J, Kim JK, Kim HG, Paek SH, Lee JW, Woo J, Kim JB, Kwon H, Lim W, Paik NS, Kim YK, Moon BI, Janku F, Tan D, Martin-Liberal J, Takahashi S, Geva R, Gucalp A, Chen X, Subramanian K, Mataraza J, Wheler J, Bedard P.

J Immunother Cancer. 2019 Feb 13;7(1):46. doi: 10.1186/s40425-019-0519-y.

44.

Predictors of In-Hospital Mortality in Korean Patients with Acute Myocardial Infarction.

Yang HY, Ahn MJ, Jeong MH, Ahn Y, Kim YJ, Cho MC, Kim CJ; and other Korea Acute Myocardial Infarction Registry Investigators.

Chonnam Med J. 2019 Jan;55(1):40-46. doi: 10.4068/cmj.2019.55.1.40. Epub 2019 Jan 25.

45.

Diphlorethohydroxycarmalol Attenuates Fine Particulate Matter-Induced Subcellular Skin Dysfunction.

Zhen AX, Piao MJ, Hyun YJ, Kang KA, Madushan Fernando PDS, Cho SJ, Ahn MJ, Hyun JW.

Mar Drugs. 2019 Feb 1;17(2). pii: E95. doi: 10.3390/md17020095.

46.

Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC.

Barlesi F, Garon EB, Kim DW, Felip E, Han JY, Kim JH, Ahn MJ, Fidler MJ, Gubens MA, de Castro G Jr, Surmont V, Li Q, Deitz AC, Lubiniecki GM, Herbst RS.

J Thorac Oncol. 2019 May;14(5):793-801. doi: 10.1016/j.jtho.2019.01.016. Epub 2019 Jan 31. Erratum in: J Thorac Oncol. 2019 Jul;14(7):1306.

PMID:
30711649
47.

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

Nam BD, Kim TJ, Park K, Ahn MJ, Choi YL, Chung MJ, Kim TS, Lee KS.

Clin Lung Cancer. 2019 May;20(3):e309-e316. doi: 10.1016/j.cllc.2018.12.021. Epub 2018 Dec 31.

PMID:
30686681
48.

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

Lee J, Sun JM, Lee SH, Ahn JS, Park K, Choi Y, Ahn MJ.

Clin Lung Cancer. 2019 May;20(3):215-221. doi: 10.1016/j.cllc.2018.12.020. Epub 2018 Dec 31.

49.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial.

Herbst RS, Baas P, Perez-Gracia JL, Felip E, Kim DW, Han JY, Molina JR, Kim JH, Dubos Arvis C, Ahn MJ, Majem M, Fidler MJ, Surmont V, de Castro G, Garrido M, Shentu Y, Emancipator K, Samkari A, Jensen EH, Lubiniecki GM, Garon EB.

Ann Oncol. 2019 Feb 1;30(2):281-289. doi: 10.1093/annonc/mdy545.

PMID:
30657853
50.

The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.

Kim KH, Cho J, Ku BM, Koh J, Sun JM, Lee SH, Ahn JS, Cheon J, Min YJ, Park SH, Park K, Ahn MJ, Shin EC.

Clin Cancer Res. 2019 Apr 1;25(7):2144-2154. doi: 10.1158/1078-0432.CCR-18-1449. Epub 2019 Jan 15.

PMID:
30647082

Supplemental Content

Support Center